Non-Muscle-Invasive Bladder Cancer (NMIBC)
AURAAura Biosciences IncCatalyst overview
Research summary
This catalyst tracks a Phase 1/2 update for Belzupacap Sarotalocan (Bel-sar) (AU-011) in Non-Muscle-Invasive Bladder Cancer (NMIBC). The expected timing is based on the latest available company guidance and may change.
10/17/24- Complete response data presented. Ongoing trial expansion and in parallel prepare for a Ph2 trial. 8/13/25- Trial actively enrolling participants. 11/13/25:- Additional immune profiling data from the completed Ph1 NMIBC trial were presented and the ongoing Ph1b/2 trial is enrolling, with initial three-month clinical data expected Mid-2026. 03/30/26:- Ph1b/2 NMIBC trial progressing; initial 3-month data remains expected Mid-2026; immune ablative and neoadjuvant cohorts described. 05/11/26:- Ph1b/2 NMIBC trial advancing; initial 3-month clinical data expected Mid-2026; immune ablative and neoadjuvant arms ongoing. 08/11/26:- Ph1b/2 interim data showed 81% ORR; NMIBC deprioritized while 12-month follow-up continues.
Verification
Confirm timing and program details against the company announcement or filing.